You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Biological Activity for TP 472
TP 472 is a potent BRD9/7 inhibitor (Kd values are 33 and 340 nM, respectively) Exhibits >30-fold selectivity for BRD9 over other bromodomains except BRD7. Cell permeable and active in vivo.
Negative Control also available.
This probe is supplied in conjunction with the Structural Genomics Consortium. For further characterization details, please visit the TP 472 probe summary on the SGC website.
Compound Libraries for TP 472
Technical Data for TP 472
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for TP 472
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions for TP 472
The following data is based on the product molecular weight 333.38. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|0.5 mM||6 mL||30 mL||59.99 mL|
|2.5 mM||1.2 mL||6 mL||12 mL|
|5 mM||0.6 mL||3 mL||6 mL|
|25 mM||0.12 mL||0.6 mL||1.2 mL|
References for TP 472
References are publications that support the biological activity of the product.
Hohmann and Vakoc et al (2014) A rationale to target the SWI/SNF complex for cancer therapy. Trends Genet. 30 356 PMID: 24932742
If you know of a relevant reference for TP 472, please let us know.
View Related Products by Product Action
Keywords: TP 472, TP 472 supplier, TP472, bromodomains, BRD9, BRD7, inhibitors, potent, CAS, 2079895-62-6, Bromodomains, 6000, Tocris Bioscience
1 Citation for TP 472
Citations are publications that use Tocris products. Selected citations for TP 472 include:
Gatchalian et al (2018) A non-canonical BRD9-containing BAF chromatin remodeling complex regulates naive pluripotency in mouse embryonic stem cells. Nat Commun 9 5139 PMID: 30510198
Do you know of a great paper that uses TP 472 from Tocris? Please let us know.
Reviews for TP 472
There are currently no reviews for this product. Be the first to review TP 472 and earn rewards!
Have you used TP 472?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Epigenetics Scientific Review
Written by Susanne Müller-Knapp and Peter J. Brown, this review gives an overview of the development of chemical probes for epigenetic targets, as well as the impact of these tool compounds being made available to the scientific community. In addition, their biological effects are also discussed. Epigenetic compounds available from Tocris are listed.
Epigenetics Research Bulletin
Produced by Tocris and updated in 2014, the epigenetics research bulletin gives an introduction into mechanisms of epigenetic regulation, and highlights key Tocris products for epigenetics targets including:
- DNA Methyltransferases
- Histone Deacetylases
- Histone Demethylases
- Histone Methyltransferases
Epigenetics in Cancer Poster
Adapted from the 2015 Cancer Product Guide Edition 3, this poster summarizes the main epigenetic targets in cancer. The dysregulation of epigenetic modifications has been shown to result in oncogenesis and cancer progression. Unlike genetic mutations, epigenetic alterations are considered to be reversible and thus make promising therapeutic targets.
Rheumatoid Arthritis Poster
Rheumatoid arthritis (RA) is a chronic destructive inflammatory autoimmune disease that results from a breakdown in immune tolerance, for reasons that are as yet unknown. This poster summarizes the pathology of RA and the inflammatory processes involved, as well as describing some of the epigenetic modifications associated with the disease and the potential for targeting these changes in the discovery of new treatments.